Published in Eur J Clin Pharmacol on August 19, 2012
Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ (2004) 21.39
The costs of adverse drug events in hospitalized patients. Adverse Drug Events Prevention Study Group. JAMA (1997) 14.57
Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 7.94
Medication-related clinical decision support in computerized provider order entry systems: a review. J Am Med Inform Assoc (2006) 6.39
Systematic overview of warfarin and its drug and food interactions. Arch Intern Med (2005) 5.86
Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther (2008) 4.54
GPs' views on computerized drug interaction alerts: questionnaire survey. J Clin Pharm Ther (2002) 4.23
Guidelines on oral anticoagulation (warfarin): third edition--2005 update. Br J Haematol (2006) 3.03
Systematic review of the incidence and characteristics of preventable adverse drug events in ambulatory care. Ann Pharmacother (2007) 2.99
Tiering drug-drug interaction alerts by severity increases compliance rates. J Am Med Inform Assoc (2008) 2.57
Drug drug interactions between antithrombotic medications and the risk of gastrointestinal bleeding. CMAJ (2007) 2.02
High-priority drug-drug interactions for use in electronic health records. J Am Med Inform Assoc (2012) 1.79
Reducing medication errors and increasing patient safety: case studies in clinical pharmacology. J Clin Pharmacol (2003) 1.70
Practitioners' views on computerized drug-drug interaction alerts in the VA system. J Am Med Inform Assoc (2006) 1.60
Prospective study of the outcomes of ambulatory patients with excessive warfarin anticoagulation. Arch Intern Med (2000) 1.55
Antidepressant-warfarin interaction and associated gastrointestinal bleeding risk in a case-control study. PLoS One (2011) 1.54
The use of failure mode effect and criticality analysis in a medication error subcommittee. Hosp Pharm (1994) 1.51
Reasons provided by prescribers when overriding drug-drug interaction alerts. Am J Manag Care (2007) 1.48
Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies. Clin Pharmacol Ther (2010) 1.36
Increased bleeding risk with concurrent use of selective serotonin reuptake inhibitors and coumarins. Arch Intern Med (2008) 1.30
Drug interactions and risk of acute bleeding leading to hospitalisation or death in patients with chronic atrial fibrillation treated with warfarin. Thromb Haemost (2005) 1.23
Influence of antidepressants on hemostasis. Dialogues Clin Neurosci (2007) 1.23
Rate, type, and cost of adverse drug reactions in emergency department admissions. Eur J Intern Med (2001) 1.19
Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol. Clin Pharmacokinet (2005) 1.18
Concurrent use of warfarin and antibiotics and the risk of bleeding in older adults. Am J Med (2012) 1.16
Antidepressants and risk of upper gastrointestinal bleeding. Basic Clin Pharmacol Toxicol (2006) 1.14
Incidence and predictors of severe bleeding during warfarin treatment. J Thromb Thrombolysis (2007) 1.09
Main comedications associated with major bleeding during anticoagulant therapy with coumarins. Eur J Clin Pharmacol (2005) 1.09
SSRIs and upper gastrointestinal bleeding: what is known and how should it influence prescribing? CNS Drugs (2006) 1.08
Cytochrome P4502C9 is the principal catalyst of racemic acenocoumarol hydroxylation reactions in human liver microsomes. Drug Metab Dispos (2000) 1.07
Warfarin and other coumarin derivatives: pharmacokinetics, pharmacodynamics, and drug interactions. Semin Vasc Med (2003) 1.06
A risk analysis method to evaluate the impact of a computerized provider order entry system on patient safety. J Am Med Inform Assoc (2008) 1.05
The effect of drug interactions on bleeding risk associated with warfarin therapy in hospitalized patients. Ann Med (2009) 1.00
Warfarin interactions with substances listed in drug information compendia and in the FDA-approved label for warfarin sodium. Clin Pharmacol Ther (2009) 1.00
Cerebral haemorrhage induced by warfarin - the influence of drug-drug interactions. Pharmacoepidemiol Drug Saf (2007) 0.98
Selective serotonin reuptake inhibitors: measurement of effect on platelet function. Transl Res (2007) 0.95
The potential for interaction between warfarin and coprescribed medication: a retrospective study in primary care. Am J Cardiovasc Drugs (2008) 0.89
The proton pump inhibitor, omeprazole, but not lansoprazole or pantoprazole, is a metabolism-dependent inhibitor of CYP2C19: implications for coadministration with clopidogrel. Drug Metab Dispos (2011) 0.89
Quantity and quality of potential drug interactions with coumarin anticoagulants in the Netherlands. Pharm World Sci (2007) 0.88
Preventing medication errors in hospitals through a systems approach and technological innovation: a prescription for 2010. Hosp Top (2006) 0.88
Major bleeding risk associated with warfarin and co-medications in the elderly population. Pharmacoepidemiol Drug Saf (2011) 0.88
Risk of hemorrhage and treatment costs associated with warfarin drug interactions in patients with atrial fibrillation. Clin Ther (2012) 0.85
Warfarin-associated bleeding events and concomitant use of potentially interacting medicines reported to the Norwegian spontaneous reporting system. Br J Clin Pharmacol (2011) 0.84
Drug interactions update: drugs, herbs, and oral anticoagulation. J Thromb Thrombolysis (2001) 0.84
Assessment of a bleeding risk index in two cohorts of patients treated with oral anticoagulants. Thromb Haemost (1996) 0.83
Effect of acetaminophen on international normalized ratio in patients receiving warfarin therapy. Pharmacotherapy (2011) 0.81
Characteristics of the amiodarone-warfarin interaction during long-term follow-up. Am J Health Syst Pharm (2008) 0.80
Risk and pharmacoeconomic analyses of the injectable medication process in the paediatric and neonatal intensive care units. Int J Qual Health Care (2010) 0.78
Simvastatin-oral anticoagulant interaction. Lancet (1996) 0.77
The role of cytochrome P2C19 in R-warfarin pharmacokinetics and its interaction with omeprazole. Ther Drug Monit (2008) 0.76
The effect of converting from pravastatin to simvastatin on the pharmacodynamics of warfarin. J Clin Pharmacol (1999) 0.76
Representing clinical narratives using conceptual graphs. Methods Inf Med (1995) 3.62
Analysis of medical texts based on a sound medical model. Proc Annu Symp Comput Appl Med Care (1995) 2.62
Neurophysiologic evidence for a central sensitization in patients with fibromyalgia. Arthritis Rheum (2003) 2.51
Modelling for natural language understanding. Proc Annu Symp Comput Appl Med Care (1993) 2.38
Risk factors for a medically inappropriate admission to a Department of Internal Medicine. Arch Intern Med (1997) 2.19
Prospective evaluation of patients with syncope: a population-based study. Am J Med (2001) 2.09
NF-κB is activated from endosomal compartments in antiphospholipid antibodies-treated human monocytes. J Thromb Haemost (2014) 2.05
Automatic extraction of linguistic knowledge from an international classification. Stud Health Technol Inform (1998) 1.83
Clinical pharmacokinetics of the third generation cephalosporins. Clin Pharmacokinet (1985) 1.70
Drug-drug interactions of new active substances: mibefradil example. Eur J Clin Pharmacol (1999) 1.63
Attitude of physicians towards automatic alerting in computerized physician order entry systems. A comparative international survey. Methods Inf Med (2012) 1.59
Contribution of monoaminergic modulation to the analgesic effect of tramadol. Br J Clin Pharmacol (1996) 1.50
Impact of a public campaign on pre-hospital delay in patients reporting chest pain. Heart (1996) 1.47
Cefoperazone: pharmacokinetics in humans with normal and impaired renal function and pharmacokinetics in rats. Clin Ther (1980) 1.44
Prolonged anti-Xa activity due to enoxaparin at the end of pregnancy. Anaesth Intensive Care (2014) 1.39
Changes in serum albumin and alpha 1-acid glycoprotein concentrations during pregnancy: an analysis of fetal-maternal pairs. Br J Obstet Gynaecol (1984) 1.35
Central analgesic effect of acetaminophen but not of aspirin. Clin Pharmacol Ther (1991) 1.30
Association between lung cancer and microsomal epoxide hydrolase genotypes. Cancer Res (1998) 1.29
The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study. J Thromb Haemost (2009) 1.28
Single-dose quinidine treatment inhibits metoprolol oxidation in extensive metabolizers. Eur J Clin Pharmacol (1986) 1.23
The AmpliChip CYP450 test: cytochrome P450 2D6 genotype assessment and phenotype prediction. Pharmacogenomics J (2008) 1.23
A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin. J Pharmacol Exp Ther (1998) 1.21
[Pharmacokinetics of a new cephalosporin, cefoperazone]. Schweiz Med Wochenschr (1979) 1.20
The power and limits of a rule-based morpho-semantic parser. Proc AMIA Symp (1999) 1.16
Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety. Br J Pharmacol (2010) 1.15
Cytochrome P450TB (CYP2C): a major monooxygenase catalyzing diclofenac 4'-hydroxylation in human liver. Life Sci (1993) 1.14
The molecular mechanisms of two common polymorphisms of drug oxidation--evidence for functional changes in cytochrome P-450 isozymes catalysing bufuralol and mephenytoin oxidation. Xenobiotica (1986) 1.14
Morpho-semantic parsing of medical expressions. Proc AMIA Symp (1998) 1.13
Mephenytoin hydroxylation polymorphism: characterization of the enzymatic deficiency in liver microsomes of poor metabolizers phenotyped in vivo. Clin Pharmacol Ther (1985) 1.12
Medical office automation integrated into the distributed architecture of a hospital information system. Methods Inf Med (1994) 1.12
Toward a medical linguistic knowledge base. Medinfo (1995) 1.10
An additional defective allele, CYP2C19*5, contributes to the S-mephenytoin poor metabolizer phenotype in Caucasians. Pharmacogenetics (1998) 1.09
Applications of CYP450 testing in the clinical setting. Mol Diagn Ther (2013) 1.08
Knowledge sources for Natural Language Processing. Proc AMIA Annu Fall Symp (1996) 1.07
The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone. Br J Pharmacol (2010) 1.06
A light knowledge model for linguistic applications. Proc AMIA Symp (2001) 1.06
Eculizumab in acute recurrence of thrombotic microangiopathy after renal transplantation. Am J Transplant (2011) 1.05
In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors. Eur J Clin Pharmacol (1996) 1.05
A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoin. J Pharmacol Exp Ther (1999) 1.05
Impact of environmental and genetic factors on codeine analgesia. Eur J Clin Pharmacol (1991) 1.05
Predictors of inappropriate hospital days in a department of internal medicine. Int J Epidemiol (1998) 1.05
Role of alcohol dehydrogenase 3 and cytochrome P-4502E1 genotypes in susceptibility to cancers of the upper aerodigestive tract. Int J Cancer (2000) 1.03
Identification of new human CYP2C19 alleles (CYP2C19*6 and CYP2C19*2B) in a Caucasian poor metabolizer of mephenytoin. J Pharmacol Exp Ther (1998) 1.03
High-activity microsomal epoxide hydrolase genotypes and the risk of oral, pharynx, and larynx cancers. Cancer Res (2000) 1.03
A transiting giant planet with a temperature between 250 K and 430 K. Nature (2010) 1.03
Reliable low-cost capillary electrophoresis device for drug quality control and counterfeit medicines. J Pharm Biomed Anal (2010) 1.00
In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (+/-)-fluvastatin. Clin Pharmacol Ther (1995) 0.99
D-dimer levels during delivery and the postpartum. J Thromb Haemost (2005) 0.99
The genetic control of bufuralol metabolism in man. Eur J Drug Metab Pharmacokinet (1982) 0.99
Lack of acetaminophen ceiling effect on R-III nociceptive flexion reflex. Eur J Clin Pharmacol (1998) 0.99
A major role for cytochrome P450TB (CYP2C subfamily) in the actions of non-steroidal antiinflammatory drugs. Drugs Exp Clin Res (1993) 0.96
Glutathione S-transferase GSTM1, GSTM3, GSTP1 and GSTT1 genotypes and the risk of smoking-related oral and pharyngeal cancers. Int J Cancer (1999) 0.95
Clinical pharmacology and rationale of analgesic combinations. Eur J Anaesthesiol Suppl (2003) 0.94
Stereoselective interaction between piroxicam and acenocoumarol. Br J Clin Pharmacol (1996) 0.93
Debrisoquine-type polymorphism of drug oxidation: purification from human liver of a cytochrome P450 isozyme with high activity for bufuralol hydroxylation. FEBS Lett (1984) 0.92
Defective hydroxylation of bufuralol associated with side-effects of the drug in poor metabolisers. Br J Clin Pharmacol (1982) 0.91
Biomedical informatics--a confluence of disciplines? Methods Inf Med (2011) 0.91
Aspirin inhibits endothelial cell activation induced by antiphospholipid antibodies. J Thromb Haemost (2004) 0.90
In vitro forecasting of drugs which may interfere with the biotransformation of midazolam. Eur J Clin Pharmacol (1991) 0.90
Versatility of a multilingual and bi-directional approach for medical language processing. Proc AMIA Symp (1998) 0.90
N-acetyltransferase NAT1 and NAT2 genotypes and lung cancer risk. Pharmacogenetics (1998) 0.90
Anti-protein S antibodies following a varicella infection: detection, characterization and influence on thrombin generation. J Thromb Haemost (2005) 0.90
Metabolic genetic polymorphisms and susceptibility to lung cancer. Lung Cancer (2001) 0.89
Looking back or looking all around: comparing two spell checking strategies for documents edition in an electronic patient record. Proc AMIA Symp (2001) 0.89
Concentrations of azithromycin in tonsilar and/or adenoid tissue from paediatric patients. J Antimicrob Chemother (1996) 0.89
Effects of beta-blockade on energy metabolism following burns. Burns (1990) 0.88
Role of glutathione S-transferase GSTM1, GSTM3, GSTP1 and GSTT1 genotypes in modulating susceptibility to smoking-related lung cancer. Pharmacogenetics (1998) 0.87
Pharmacokinetic-pharmacodynamic modeling of the effects of clonidine on pain threshold, blood pressure, and salivary flow. Eur J Clin Pharmacol (1992) 0.87
Simultaneous tubular excretion and reabsorption of pindolol in man. Eur J Clin Pharmacol (1981) 0.87
[Duality of the analgesic effect of tramadol in humans]. Schweiz Med Wochenschr (1993) 0.86
Recommendations on testing for thrombophilia in venous thromboembolic disease: a French consensus guideline. J Mal Vasc (2009) 0.86
Conceptual search in electronic patient record. Stud Health Technol Inform (2001) 0.85
50 years of informatics research on decision support: what's next. Methods Inf Med (2011) 0.85
Differences in kinetic properties of drugs: implications as to the selection of a particular drug for use in patients with renal failure with special emphasis on antibiotics and beta-adrenoceptor blocking agents. Clin Pharmacokinet (1980) 0.85
Larynx cancer risk in relation to glutathione S-transferase M1 and T1 genotypes and tobacco smoking. Cancer Epidemiol Biomarkers Prev (1998) 0.85
Do physicians modify their prehospital management of patients in response to a public campaign on chest pain? Am J Cardiol (1998) 0.85
Measuring human-error probabilities in drug preparation: a pilot simulation study. Eur J Clin Pharmacol (2007) 0.85
[Potassium chloride and non-specific ulcers in the small intestine]. Schweiz Med Wochenschr (1977) 0.84
Integrated computerized patient records: the DIOGENE 2 distributed architecture paradigm with special emphasis on its middleware design. Stud Health Technol Inform (1998) 0.84
Impact of genetic polymorphisms and drug-drug interactions on clopidogrel and prasugrel response variability. Curr Drug Metab (2010) 0.84
Alternative ways for knowledge collection, indexing and robust language retrieval. Methods Inf Med (1998) 0.84
TAFI antigen and D-dimer levels during normal pregnancy and at delivery. Br J Haematol (2001) 0.84
Glutathione S-transferase GSTM3 and GSTP1 genotypes and larynx cancer risk. Cancer Epidemiol Biomarkers Prev (1999) 0.84
C-reactive protein as a marker for acute coronary syndromes. Eur Heart J (1997) 0.84
Oral flurbiprofen metabolic ratio assessment using a single-point dried blood spot. Clin Pharmacol Ther (2012) 0.84
Indirect assessment of the enterohepatic recirculation of piroxicam and tenoxicam. Eur J Clin Pharmacol (1990) 0.83
Once-a-week azithromycin in AIDS patients: tolerability, kinetics, and effects on zidovudine disposition. Antimicrob Agents Chemother (1992) 0.83
Interindividual variation of beta-adrenoceptor blocking drugs, plasma concentration and effect: influence of genetic status on behaviour of atenolol, bopindolol and metoprolol. Eur J Clin Pharmacol (1985) 0.83
Role of human liver microsomal CYP2C9 in the biotransformation of lornoxicam. Eur J Clin Pharmacol (1996) 0.83
Radiation recall in a patient with breast cancer treated for tuberculosis. Eur J Clin Pharmacol (1995) 0.82
Full text multilingual automatic morphosemantems for stand-alone or Internet based applications. Stud Health Technol Inform (1998) 0.82
Contribution of cytochrome P-4502D6 phenotype to the neuromodulatory effects of dextromethorphan. J Pharmacol Exp Ther (1999) 0.82
Development and validation of a chemical hydrolysis method for dextromethorphan and dextrophan determination in urine samples: application to the assessment of CYP2D6 activity in fibromyalgia patients. J Chromatogr B Analyt Technol Biomed Life Sci (2007) 0.82